Spark's CSO is wrapping up animal studies on a gene therapy for Pompe disease as new work in the field sees explosive growth
When Federico Mingozzi joined Spark Therapeutics $ONCE last fall as their new chief scientific officer, he brought along several years worth of preclinical work on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
